Latest by Barbara Jungwirth
Anticholinergics and cognitive performance; gender, physical activity, and cognitive decline; how peer networks can boost HIV self-testing among MSM of color; what HIV care providers don’t know about the Affordable Care Act.
Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.
The Medicines Patent Pool, which negotiates licenses with the manufacturers of new drugs that allow other companies to produce generic versions for distribution in low- and middle-income countries, is looking to expand beyond HIV drugs to medications...
Alcohol use worsens HIV care outcomes; sex-based differences in cognitive performance seen; higher cardiovascular risk among trans women; glycemic status related to cognitive function.
While almost 60% of people living with HIV globally are on treatment, the numbers for new seroconversions averted and HIV-related deaths are no longer improving.
In a recent survey of people not living with HIV, many still believed that people living with HIV should not be allowed to work in hospitals, restaurants, or universities, among other occupations, and 68% said they would be uncomfortable dating someo...
After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.
Early treatment reduces health risks; on-demand PrEP more popular than daily pill among French MSM; long-acting injectable PrEP preferred over daily pill in Swaziland; HIV-positive MSM aren’t testing for syphilis enough.
“Opposites Attract” study piles on more data backing U=U; mixed results on enhanced HIV interventions among African sex workers; the tipping point for re-engagement in HIV care; thyroid function in the modern treatment era.
Dolutegravir-Based Two-Drug Regimen Just as Good for HIV Treatment as Three-Drug Therapy, Study Says
A dolutegravir-based two-drug regimen was non-inferior to the standard three-drug therapy among treatment-naive participants, according to results from the two GEMINI trials presented at the International AIDS Conference in Amsterdam, the Netherlands...